• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bruker Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    9/8/25 4:21:37 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    false12-31000110935400011093542025-09-032025-09-030001109354brkr:Six375MandatoryConvertiblePreferredStockSeriesAMember2025-09-032025-09-030001109354us-gaap:CommonStockMember2025-09-032025-09-03

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549


     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): September 3, 2025

    Bruker Corporation
    (Exact name of registrant as specified in its charter)
     
    Delaware
    000-30833
    04-3110160
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    40 Manning Road
    Billerica, MA
    (Address of principal executive offices)
     
    01821
    (Zip Code)
     
     (978) 663-3660
    (Registrant’s telephone number, including area code)
     
    NOT APPLICABLE
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.01 par value per share
     
    BRKR
     
    NASDAQ
    6.375% Mandatory Convertible Preferred Stock, Series A
     
    BRKRP
     
    NASDAQ
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec.230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec.240.12b-2 of this chapter).

    ☐
    Emerging growth company

    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
     


    Item 3.03
    Material Modification of Rights of Security Holders.
     
    On September 8, 2025, Bruker Corporation (the “Company”) issued 2,760,000 shares, or $690,000,000 aggregate liquidation preference, of its 6.375% Mandatory Convertible Preferred Stock, Series A (the “Mandatory Convertible Preferred Stock”) (including 360,000 shares, or $90,000,000 aggregate liquidation preference, of Mandatory Convertible Preferred Stock issued upon exercise by the underwriters of over-allotment option in full) pursuant to a previously announced underwritten public offering (the “Offering”). In connection with the issuance of the Mandatory Convertible Preferred Stock, the Company filed a Certificate of Designations (the “Certificate of Designations”) with the Secretary of State of the State of Delaware on September 8, 2025 to establish the designations, powers, preferences and rights of the Mandatory Convertible Preferred Stock and the qualifications, limitations and restrictions thereof, including the dividend rate, the amount payable with respect thereto in the event of the Company’s voluntary or involuntary liquidation, winding-up or dissolution, restrictions on the issuance of shares of the same series or of any other class or series, the terms and conditions of conversion of the Mandatory Convertible Preferred Stock and the voting rights of the Mandatory Convertible Preferred Stock. The Certificate of Designations became effective upon such filing.
     
    Subject to certain exceptions, so long as any share of Mandatory Convertible Preferred Stock remains outstanding, no dividend or distributions will be declared or paid on shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), or any other class or series of stock ranking junior to the Mandatory Convertible Preferred Stock, and no Common Stock or any other class or series of stock ranking junior to the Mandatory Convertible Preferred Stock will be purchased, redeemed, or otherwise acquired for consideration by the Company or any of its subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid in cash, shares of Common Stock or a combination thereof, or a sufficient sum of cash or number of shares of Common Stock has been set aside for the payment of such dividends, on all outstanding shares of Mandatory Convertible Preferred Stock.  In addition, when dividends on shares of the Mandatory Convertible Preferred Stock (i) have not been declared and paid in full on any dividend payment date, or (ii) have been declared but a sum of cash or number of shares of Common Stock sufficient for payment thereof has not been set aside for the benefit of the holders thereof on the applicable regular record date, no dividends may be declared or paid on any parity stock unless dividends are declared on the shares of Mandatory Convertible Preferred Stock such that the respective amounts of such dividends declared on the shares of Mandatory Convertible Preferred Stock and such shares of parity stock shall be allocated pro rata among the holders of the shares of Mandatory Convertible Preferred Stock and the holders of any shares of parity stock then outstanding.
     
    Unless converted earlier in accordance with the terms of the Certificate of Designations, each share of the Mandatory Convertible Preferred Stock will automatically convert on the mandatory conversion date, which is expected to be September 1, 2028, into between 6.9534 shares and 8.5179 shares of Common Stock, in each case, subject to customary anti-dilution adjustments described in the Certificate of Designations. The number of shares of Common Stock issuable upon mandatory conversion will be determined based on the average volume weighted average price per share of Common Stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately prior to September 1, 2028.
     
    Dividends on the Mandatory Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by the Company’s board of directors, or an authorized committee thereof, at an annual rate of 6.375% on the liquidation preference of $250.00 per share of Mandatory Convertible Preferred Stock, and may be paid in cash or, subject to certain limitations, in shares of Common Stock or, subject to certain limitations, any combination of cash and shares of Common Stock. If declared, dividends on the Mandatory Convertible Preferred Stock will be payable quarterly on March 1, June 1, September 1 and December 1 of each year to, and including, September 1, 2028, commencing on December 1, 2025.
     
    Upon the Company’s voluntary or involuntary liquidation, winding-up or dissolution, each holder of the Mandatory Convertible Preferred Stock will be entitled to receive a liquidation preference in the amount of $250.00 per share of Mandatory Convertible Preferred Stock, plus an amount equal to accumulated and unpaid dividends on such shares, whether or not declared, to, but excluding, the date fixed for liquidation, winding-up or dissolution, such amount to be paid out of the Company’s assets legally available for distribution to its stockholders after satisfaction of debt and other liabilities owed to the Company’s creditors and holders of shares of its stock ranking senior to the Mandatory Convertible Preferred Stock and before any payment or distribution is made to holders of any stock ranking junior to the Mandatory Convertible Preferred Stock, including, without limitation, Common Stock.
     
    The foregoing description of the terms of the Mandatory Convertible Preferred Stock and the Certificate of Designations in this Item 3.03 is qualified in its entirety by reference to the Certificate of Designations, which is included as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.
     
    Item 5.03
    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
     
    The information set forth above under Item 3.03 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 5.03.


    Item 8.01
    Other Events.
     
    On September 3, 2025, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several underwriters named therein relating to the Offering.
     
    The net proceeds from the Offering were approximately $669.5 million, after deducting underwriting discounts and estimated offering expenses.
     
    Item 9.01
    Financial Statements and Exhibits.
     
    (d)          Exhibits.
     
    The following documents are herewith filed or furnished as exhibits to this Current Report on Form 8-K:
     
    Exhibit No.
     
    Exhibit Description
    1.1
     
    Underwriting Agreement relating to the Mandatory Convertible Preferred Stock, dated September 3, 2025 among Bruker Corporation and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the underwriters.
    3.1
     
    Certificate of Designations of 6.375% Mandatory Convertible Preferred Stock, Series A of Bruker Corporation
    4.1
     
    Form of 6.375% Mandatory Convertible Preferred Stock, Series A Certificate (included within Exhibit 3.1).
    5.1
     
    Opinion of Simpson Thacher & Bartlett LLP regarding the legality of the shares of Mandatory Convertible Preferred Stock, dated September 8, 2025.
    23.1
     
    Consent of Simpson Thacher & Bartlett LLP (included in Exhibit 5.1).
    104
     
    Cover Page Interactive Data File (embedded within Inline XBRL document).


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    BRUKER CORPORATION
         
    Date: September 8, 2025
    By:
    /s/ Gerald N. Herman
     
    Name:
    Gerald N. Herman
     
    Title:
    Executive Vice President and Chief Financial Officer



    Get the next $BRKR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    More analyst ratings

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock

    Bruker Corporation ("Bruker") (NASDAQ:BRKR) today announced the pricing of its previously announced public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock"). Bruker has granted the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock. The offering is expected to close on or about September 8, 2025, subject to customary closing conditions. Bruker estimates that the net proceeds from this offering will be approximately $582.0 million (or approximately $669.5 million if the underwriters exercise their option to purchase Man

    9/3/25 11:37:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Public Offering of $600 Million of Mandatory Convertible Preferred Stock

    Bruker Corporation ("Bruker") (NASDAQ:BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock"). Bruker expects to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock, solely to cover over-allotments, if any. Bruker intends to use the net proceeds from this offering to strengthen the balance sheet and enhance strategic flexibility by repaying (i) its term loan due December 2026 in full, (ii) outstanding borrowings under its 2024 amended

    9/2/25 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Quarterly Dividend

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and

    8/12/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H was granted 48,431 shares, increasing direct ownership by 0.13% to 38,494,103 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/19/25 4:15:28 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT, BIOSPIN GROUP Busse Falko was granted 9,282 shares, increasing direct ownership by 24% to 48,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/19/25 4:15:25 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark was granted 23,631 shares, increasing direct ownership by 23% to 128,443 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/19/25 4:15:20 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    SEC Filings

    View All

    SEC Form CERT filed by Bruker Corporation

    CERT - BRUKER CORP (0001109354) (Filer)

    9/8/25 4:56:01 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-A12B filed by Bruker Corporation

    8-A12B - BRUKER CORP (0001109354) (Filer)

    9/8/25 4:40:42 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    9/8/25 4:21:37 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker downgraded by Citigroup with a new price target

    Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00

    5/22/25 8:18:13 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Bruker with a new price target

    Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

    12/19/24 7:30:10 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    UBS initiated coverage on Bruker with a new price target

    UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

    12/10/24 8:26:42 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Announces Quarterly Dividend

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and

    8/12/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on August 4, 2025

    Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the second quarter ended June 30, 2025 in a range of $795 - $798 million, which implies approximately flat reported revenue year-over-year. Bruker estimates that its non-GAAP organic revenue in the second quarter of 2025 declined approximately 7% year-over-year, with constant-exchange rate revenue declining approximately 3%. Second quarter 2025 bookings reflect weak academic demand, as well as softness in the U.S. biopharma market. Second quarter 2025 non-GAAP EPS is expected in the $0.32 - $0.34 range, representing approximately a $0.19 per share decline year-over-year, including a $0.06 foreign currency headwind.

    7/21/25 8:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

    Acquisition further expands Bruker's multiomics strategy with biocrates metabolomics kits and assays, and related software and research services Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603323690/en/biocrates kits and pipettes biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits co

    6/3/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials